CD79A and COVID-19: This was also found by Hasan Ali et al., who compared two cohorts with mild and severe COVID-19 and observed significantly elevated IgA anti-CL and IgA anti-β2GPI in the severe COVID-19 cohort [22], and by Garcia-Arellano et al., who found a significantly higher prevalence of IgA anti-β2GPI in moderate to severe COVID-19 patients [37].